New drug combo aims to boost cancer-killing power of standard thyroid treatment
NCT ID NCT05783323
Summary
This study is testing whether a drug called larotrectinib can make radioactive iodine treatment more effective for people with advanced thyroid cancer that has spread to the lungs. Participants will take larotrectinib for six months, then receive standard radioactive iodine therapy. The main goal is to see if this combination helps shrink or eliminate lung tumors better than radioactive iodine alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 19807, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94115, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.